[go: up one dir, main page]

SG11201909949XA - Targeted immunotolerance - Google Patents

Targeted immunotolerance

Info

Publication number
SG11201909949XA
SG11201909949XA SG11201909949XA SG11201909949XA SG 11201909949X A SG11201909949X A SG 11201909949XA SG 11201909949X A SG11201909949X A SG 11201909949XA SG 11201909949X A SG11201909949X A SG 11201909949XA
Authority
SG
Singapore
Prior art keywords
international
street
massachusetts
pct
olo
Prior art date
Application number
Inventor
Joanne L Viney
Nathan Higginson-Scott
Original Assignee
Pandion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pandion Therapeutics Inc filed Critical Pandion Therapeutics Inc
Publication of SG11201909949XA publication Critical patent/SG11201909949XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compounds for conferring site-specific or local immune privilege. W O 20 18/ 217 989 Al TARGETING Say DOMAINS FIG. 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 November 2018 (29.11.2018) WIPO I PCT ~~ll~~~~~~~~ 011101VIIIVIIIVIII olo oi olo VIII 0111110/ ow (10) International Publication Number WO 2018/217989 Al (51) International Patent Classification: A61K 38/20 (2006.01) C07K 14/55 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2018/034334 (22) International Filing Date: 24 May 2018 (24.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/510,586 24 May 2017 (24.05.2017) US 62/510,816 25 May 2017 (25.05.2017) US 62/558,175 13 September 2017 (13.09.2017) US 62/595,352 06 December 2017 (06.12.2017) US (71) Applicant: PANDION THERAPEUTICS, INC. [US/US]; 700 Main Street, North, Cambridge, Massachu- setts 02139 (US). (72) Inventors: VINEY, Joanne L.; 30 Common Street, Bel- mont, Massachusetts 02478 (US). HIGGINSON-SCOTT, Nathan; 623 Tremont Street, Apt. 3, Boston, Massachusetts 02118 (US). = (74) Agent: SCOLNICK, Daniel M.; Pepper Hamilton LLP, 19th Floor, High Street Tower, 125 High Street, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: TARGETED IMMUNOTOLERANCE
SG11201909949X 2017-05-24 2018-05-24 Targeted immunotolerance SG11201909949XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762510586P 2017-05-24 2017-05-24
US201762510816P 2017-05-25 2017-05-25
US201762558175P 2017-09-13 2017-09-13
US201762595352P 2017-12-06 2017-12-06
PCT/US2018/034334 WO2018217989A1 (en) 2017-05-24 2018-05-24 Targeted immunotolerance

Publications (1)

Publication Number Publication Date
SG11201909949XA true SG11201909949XA (en) 2019-11-28

Family

ID=64395920

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909949X SG11201909949XA (en) 2017-05-24 2018-05-24 Targeted immunotolerance

Country Status (12)

Country Link
US (2) US10676516B2 (en)
EP (1) EP3630163A4 (en)
JP (1) JP2020521452A (en)
KR (1) KR20200010354A (en)
CN (1) CN111010866A (en)
AU (1) AU2018273914A1 (en)
BR (1) BR112019024127A2 (en)
CA (1) CA3064435A1 (en)
IL (1) IL270741A (en)
MX (1) MX2019013517A (en)
SG (1) SG11201909949XA (en)
WO (1) WO2018217989A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311606A1 (en) * 2014-09-05 2017-04-27 Gemma Alexandra Figtree Methods for treatment and prevention of vascular disease
KR102050463B1 (en) 2016-08-10 2019-11-29 아주대학교산학협력단 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
US20210277085A1 (en) * 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (en) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Partial agonist of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
MX2020005208A (en) * 2017-12-06 2020-08-20 Pandion Operations Inc Il-2 muteins and uses thereof.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7554742B2 (en) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド Anti-TCR antibody molecules and uses thereof
EP3876986A4 (en) * 2018-09-18 2022-06-01 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
CA3117212A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
US20220056094A1 (en) * 2018-12-21 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Human interleukin-2 variant or derivative thereof
SG11202106700WA (en) * 2019-01-07 2021-07-29 Inhibrx Inc Polypeptides comprising modified il-2 polypeptides and uses thereof
CN114127111B (en) 2019-02-21 2024-09-10 马伦戈治疗公司 Antibody molecules binding to NKP30 and uses thereof
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020256868A1 (en) * 2019-05-16 2020-12-24 Trustees Of Boston University Immune system modulators for the treatment of squamous lung premalignancy
CN114679909A (en) * 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM-targeted immune tolerance
CA3142738A1 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
CA3143038A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
TWI889694B (en) 2019-07-26 2025-07-11 美商威特拉公司 Interleukin-2 agents and uses thereof
WO2021030374A1 (en) * 2019-08-15 2021-02-18 Cytimm Therapeutics, Inc. Modified interleukin 2 (il-2) polypeptides, conjugates and uses thereof
TWI890718B (en) 2019-12-20 2025-07-21 美商再生元醫藥公司 Novel il2 agonists and methods of use thereof
KR20220140514A (en) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 Modified IL-2 polypeptides and uses thereof
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US20240262905A1 (en) * 2020-10-16 2024-08-08 Pandion Operations, Inc. Skin targeted immunotolerance
US20250019431A1 (en) * 2020-10-16 2025-01-16 Pandion Operations, Inc. Kidney targeted immunotolerance
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
MX2023006599A (en) 2020-12-04 2023-06-19 Visterra Inc Methods of using interleukin-2 agents.
IL307574A (en) * 2021-04-16 2023-12-01 Orionis Biosciences Inc constructs based on IL-2
WO2022235622A2 (en) * 2021-05-04 2022-11-10 Biocove Llc Cd20 targeting fusion proteins and methods of use thereof
US20230303649A1 (en) 2021-07-09 2023-09-28 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
AU2023295521A1 (en) 2022-06-16 2025-01-02 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof

Family Cites Families (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (en) 1982-10-19 1991-02-11 Cetus Corp FOERFARANDE FOER FRAMSTAELLNING AV IL-2 MUTEIN.
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
AU3285989A (en) 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
NZ234674A (en) 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US20040115128A1 (en) 1995-09-08 2004-06-17 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
EP1442750B1 (en) 1997-11-20 2012-08-01 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
CA2641217A1 (en) 1997-11-20 1999-06-03 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
DZ2788A1 (en) 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
EP1100830B1 (en) 1998-07-28 2003-10-01 Micromet AG Heterominibodies
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
US20030021792A1 (en) 2001-06-08 2003-01-30 Roben Paul W. Tissue-specific endothelial membrane proteins
WO2001024814A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US20020041865A1 (en) * 2000-01-20 2002-04-11 Richard Austin Methods for treating tumors
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
CN100503639C (en) * 2001-05-03 2009-06-24 默克专利有限公司 Recombinant tumor specific antibody and use thereof
JP2005507870A (en) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア Low toxicity interleukin-2 mutant
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
ATE542137T1 (en) 2001-12-04 2012-02-15 Merck Patent Gmbh IMMUNOCYTOKINE WITH MODULATED SELECTIVITY
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
US20070202097A1 (en) 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DE602004031341D1 (en) 2003-07-21 2011-03-24 Transgene Sa MULTIFUNCTIONAL CYTOKINE
DK1648931T3 (en) 2003-07-21 2011-03-07 Transgene Sa Multifunctional cytokines
KR100632985B1 (en) 2003-07-26 2006-10-11 메덱스젠 주식회사 Methods for Enhancing the Potency of Bioactive Regulatory Proteins and Exemplary Variants
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005062929A2 (en) 2003-12-22 2005-07-14 Chiron Coporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
MX350383B (en) 2004-01-09 2017-09-04 Pfizer ANTIBODIES AGAINST MADCAM.
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
DK1765860T3 (en) 2004-05-19 2009-03-09 Immunocore Ltd New-ESO-T. cell receptor with high affinity
US8815235B2 (en) 2004-06-02 2014-08-26 Jan E. Schnitzer Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
MX2007009012A (en) 2005-01-27 2007-09-14 Novartis Vaccines & Diagnostic Methods for treating renal cell carcinoma.
WO2006089064A1 (en) 2005-02-15 2006-08-24 Novartis Vaccines And Diagnostics Inc. Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
CA2600608A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PL1899364T5 (en) 2005-05-17 2024-12-09 University Of Connecticut Compositions and methods for immunomodulation in an organism
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
EA018030B1 (en) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Human binding molecules having killing activity against staphylococci and use thereof
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8470323B2 (en) 2007-01-09 2013-06-25 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
US8298545B2 (en) 2007-02-07 2012-10-30 The Trustees Of The University Of Pennsylvania Anti-autoimmune antibodies for treatment of pemphigus
EP2131856B1 (en) 2007-03-07 2014-09-17 UTI Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2009002380A2 (en) 2007-06-26 2008-12-31 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AU2008329530A1 (en) 2007-11-28 2009-06-04 Universite De Montreal PD-1 modulation and uses thereof
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
HRP20180045T1 (en) 2008-10-02 2018-03-23 Aptevo Research And Development Llc Cd86 antagonist multi-target binding proteins
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CN102196815A (en) 2008-10-21 2011-09-21 默克专利有限公司 Cancer treatments with radiation and immunocytokines
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
US8815297B2 (en) 2009-03-31 2014-08-26 Duke University Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
JP2013501817A (en) 2009-08-14 2013-01-17 アメリカ合衆国 Use of IL-15 for treatment of increased thymic output and lymphopenia
CU23734A1 (en) 2009-11-27 2011-11-15 Centro Inmunologia Molecular IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
RS55229B1 (en) 2009-12-29 2017-02-28 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND THEIR USES
BR112012022672B1 (en) 2010-03-10 2020-04-14 Genmab As monoclonal antibody, nucleotide sequence, expression vector, recombinant prokaryotic host cell, pharmaceutical composition, use of the antibody, methods to produce an antibody, to detect the presence of c-met in a sample, and, kit to detect the presence of c -met in a sample
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
CA2816722C (en) 2010-11-12 2022-03-15 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPER-AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
PL3075745T3 (en) 2011-02-10 2019-07-31 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012112426A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
EP2681245B1 (en) 2011-03-03 2018-05-09 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP3766513A1 (en) 2011-03-11 2021-01-20 Assistance Publique Hôpitaux de Paris Use of low dosage il-2 for treating vasculitis
ES2811624T3 (en) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique IL-2 Dosage Regimen to Treat Systemic Lupus Erythematosus
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
WO2012163519A1 (en) 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
AU2012275390A1 (en) 2011-06-28 2014-01-16 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2013043529A1 (en) 2011-09-19 2013-03-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
HUE056462T2 (en) 2011-11-04 2022-02-28 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
SI3431492T1 (en) 2012-04-27 2021-07-30 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2876293C (en) 2012-06-27 2023-10-10 Arthrogen B.V. Combination for treating an inflammatory disorder
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN112587658A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted Immunotherapy for Cancer
JP6290209B2 (en) 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー A composition comprising two antibodies engineered to have reduced and increased effector function.
CN104968686B (en) 2012-12-05 2020-02-04 薛富盛 Chemokine-cytokine fusion protein and application thereof
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2907181C (en) * 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
EP2994530A4 (en) 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE
CN104395342B (en) 2013-06-06 2017-07-04 合肥立方制药股份有限公司 The antibody in the anti-fibronectin ED B structures domain in people source and application thereof
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
EA201992609A1 (en) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS
US10323077B2 (en) 2014-02-10 2019-06-18 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
ES2864124T3 (en) 2014-03-11 2021-10-13 Molecular Templates Inc Proteins comprising binding regions, effector regions of Shiga toxin A subunit, and carboxy-terminal endoplasmic reticulum localization signal motifs
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
JP6768633B2 (en) 2014-07-21 2020-10-14 デリニア， インコーポレイテッド Molecules that selectively activate regulatory T cells to treat autoimmune diseases
JP6749312B2 (en) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Optimized interspecific bispecific single chain antibody constructs
PT3177644T (en) 2014-08-05 2021-01-13 MabQuest SA Immunological reagents binding to pd-1
MA40094B1 (en) 2014-08-06 2022-05-31 Univ Miami Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
HUE051414T2 (en) 2014-08-11 2021-03-01 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2016025642A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
RU2710354C2 (en) 2014-08-29 2019-12-25 Ф.Хоффманн-Ля Рош Аг Combined therapy based on tumour-targeted immunocytokines containing variant il-2, and antibodies to human pd-l1
EP3590962B1 (en) 2014-10-23 2021-09-29 Singh Molecular Medicine, LLC Single domain antibodies directed against intracellular antigens
US10793613B2 (en) 2014-12-15 2020-10-06 Washington University Compositions and methods for targeted cytokine delivery
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer MADCAM ANTAGONIST DOSING REGIMEN
US20170369871A1 (en) 2015-01-12 2017-12-28 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
BR112017019559B1 (en) 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE OF THESE
WO2016164656A1 (en) 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
SG10201907164SA (en) 2015-04-22 2019-09-27 Curevac Ag Rna containing composition for treatment of tumor diseases
US20180154012A1 (en) 2015-05-05 2018-06-07 Rubicon Biotechnology Llc Cancer immunotherapeutic
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
CN114425077A (en) 2015-05-18 2022-05-03 起源生物医药公司 SIRP polypeptide compositions and methods of use
EP4272757A3 (en) 2015-06-10 2023-12-27 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
AU2016281641B2 (en) 2015-06-23 2022-01-20 Eureka Therapeutics, Inc. Novel PD-1 immune modulating agents
US20180256747A1 (en) 2015-06-30 2018-09-13 Nanotics, Llc Compositions and methods related to scavenger particles
US10653790B2 (en) 2015-07-29 2020-05-19 Nanotics, Llc Compositions and methods related to scavenger particles
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
TWI617319B (en) * 2015-09-01 2018-03-11 免疫功坊股份有限公司 Fusion proteins for treating pathological blood clots
KR102739782B1 (en) 2015-09-11 2024-12-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Biologically relevant orthogonal cytokine/receptor pairs
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
MX2018003689A (en) 2015-09-29 2018-04-30 Celgene Corp Pd-1 binding proteins and methods of use thereof.
CA3001429C (en) 2015-10-22 2023-07-11 Iltoo Pharma Pharmaceutical compositions of il-2
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
CN109071648B (en) 2015-10-23 2022-07-19 辉瑞有限公司 anti-IL-2 antibodies and compositions and uses thereof
US20170232070A1 (en) 2015-10-23 2017-08-17 Richard P. Junghans Combination Methods for Immunotherapy
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10597466B2 (en) 2015-12-02 2020-03-24 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
JP7325186B2 (en) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Type II anti-CD20 antibody for reducing the formation of anti-drug antibodies
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN108430511B (en) 2015-12-21 2021-06-04 合肥立方制药股份有限公司 Drug design method, obtained drug and application thereof
MA43859A (en) 2016-01-11 2018-11-21 Novartis Ag HUMANIZED MONOCLONAL ANTIBODIES IMMUNOSTIMULANTS DIRECTED AGAINST HUMAN INTERLEUKIN -2, AND THEIR FUSION PROTEINS
WO2017121758A1 (en) 2016-01-11 2017-07-20 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
RU2760997C2 (en) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Compositions and methods for treating type 1 diabetes
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
ES2981745T3 (en) 2016-02-05 2024-10-10 Orionis Biosciences BV Bispecific signaling agents and their uses
JP7220458B2 (en) 2016-02-05 2023-02-10 ワシントン・ユニバーシティ Compositions and methods for targeted cytokine delivery
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
ES2718192T3 (en) 2016-02-25 2019-06-28 Provecs Medical Gmbh Novel immunostimulatory vector system
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
JP2019512233A (en) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー Method of producing and therapeutic use of monomeric diphtheria toxin fusion proteins free of aggregates
JP6911044B2 (en) 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ Combination of glucocorticoid and polyethylene glycol-modified interleukin 2 for the treatment of respiratory diseases
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
JP6732041B2 (en) 2016-04-12 2020-07-29 フィロジェン ソチエタ ペル アツィオーニ Combination therapy comprising inflammatory immune cytokines and chimeric antigen receptor (CAR)-T cells
EP3443003B1 (en) 2016-04-15 2020-12-30 Philogen S.p.A. Non-glycosylated anti-tenascin antibody
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20250133490A (en) 2016-05-04 2025-09-05 암젠 인크 Interleukin-2 muteins for the expansion of t-regulatory cells
JP2019518786A (en) 2016-05-06 2019-07-04 牧林 王 Interleukin combinations and uses thereof
GB201608192D0 (en) 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
CN109689694B (en) 2016-05-19 2022-11-22 通用医疗公司 IL2 binding to its receptor IL-2Rβ serves as a platform for enhancing the activity of natural killer cells and regulatory T cells
MX2018014432A (en) 2016-05-25 2019-04-01 Hoffmann La Roche Materials and methods relating to dosage regimen design.
MX2018014602A (en) 2016-05-27 2019-06-10 Etubics Corp Neoepitope vaccine compositions and methods of use thereof.
WO2017210579A1 (en) 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
US20190125852A1 (en) 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CN109862939A (en) 2016-06-03 2019-06-07 埃特彼塞斯公司 Compositions and methods for treating human papillomavirus (HPV) related diseases
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
PL3475413T3 (en) 2016-06-22 2024-07-22 David Klatzmann Genetically modified t lymphocytes
US11141463B2 (en) 2016-07-11 2021-10-12 The National Institute for Biotechnology in the Negev Ltd. Fusion proteins with extended serum half life
CN109843323B (en) 2016-07-15 2022-06-07 埃特彼塞斯公司 Compositions and methods for flavivirus vaccination
EP3484508A4 (en) 2016-07-15 2020-03-25 Etubics Corporation COMPOSITIONS AND METHODS FOR ALPHAVIRUS VACCINATION
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
CN109890405A (en) 2016-08-19 2019-06-14 布鲁克林免疫治疗有限公司 Use of PD-1/PD-L1 inhibitor and/or CTLA-4 inhibitor and biologics containing multiple cytokine components for the treatment of cancer
EP3512875A2 (en) 2016-09-15 2019-07-24 Quadrucept Bio Limited Multimers, tetramers&octamers
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017331277B2 (en) 2016-09-23 2024-05-30 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CA3036713A1 (en) 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3538130A4 (en) 2016-11-10 2020-06-03 Nektar Therapeutics Immunotherapeutic tumor treatment method
US10011269B2 (en) 2016-11-30 2018-07-03 Ford Global Technologies, Llc Identifying in-range fuel pressure sensor error
KR20190094222A (en) 2016-12-13 2019-08-12 데리니아, 인크. Multivalent Regulatory T Cell Modulators
US20190352361A1 (en) 2016-12-15 2019-11-21 The Brigham And Women`S Hospital, Inc. Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
WO2018129188A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
IL299915A (en) 2017-01-04 2023-03-01 Nanotics Llc Methods for assembling scavenging particles
IL267780B2 (en) 2017-01-06 2024-11-01 Iovance Biotherapeutics Inc Expansion of infiltrating lymphocytes (TILS) with TNFRSF receptor superfamily agonists and therapeutic combinations of TILS and TNFRSF agonists
CN110168078B (en) 2017-01-06 2024-05-14 免疫生物公司 Genetically modified NK-92 cells with reduced CD96/TIGIT expression
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US12350303B2 (en) 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
ES3018262T3 (en) 2017-02-16 2025-05-14 Sonnet Biotherapeutics Inc Albumin binding domain fusion proteins
KR20190121773A (en) 2017-03-01 2019-10-28 넥타르 테라퓨틱스 Immunotherapy Tumor Therapy Using Interleukin-2 Receptor Alpha, Beta Selective Agonists in Combination with Adoptive Cell Transplantation Therapy
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CN110392692B (en) 2017-04-03 2023-07-21 豪夫迈·罗氏有限公司 Immunoconjugates of anti-PD-1 antibody with mutant IL-2 or with IL-15
CN108686202A (en) 2017-04-06 2018-10-23 张晋宇 tumour immunotherapy
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
MX2019012187A (en) 2017-04-13 2019-11-25 Hoffmann La Roche An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer.
BR112018075281A2 (en) 2017-05-10 2020-02-11 Wellstat Immuno Therapeutics, Llc ENVELOPED VIRUS RESISTANT TO INACTIVATION BY COMPLEMENT FOR CANCER TREATMENT
TW201904578A (en) 2017-05-10 2019-02-01 美商艾歐凡斯生物治療公司 Amplification of tumor infiltrating lymphocytes derived from liquid tumors and therapeutic use of the expanded tumor infiltrating lymphocytes
EP3634980B1 (en) 2017-05-15 2023-07-19 University of Miami Materials and methods for subjects at risk for viral reactivation
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
WO2019112852A1 (en) 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US20210277085A1 (en) 2017-05-24 2021-09-09 Pandion Therapeutics, Inc. Targeted immunotolerance
PE20200303A1 (en) 2017-05-24 2020-02-06 Novartis Ag ANTIBODY PROTEINS GRAFTED WITH CYTOKINE AND METHODS OF USE IN THE TREATMENT OF CANCER
JP2020520671A (en) 2017-05-24 2020-07-16 ノバルティス アーゲー Antibody-cytokine grafted proteins and methods of use
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2018227018A1 (en) 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
JP7362596B2 (en) 2017-06-12 2023-10-17 オブシディアン セラピューティクス， インコーポレイテッド PDE5 compositions and methods for immunotherapy
EP3638700B8 (en) 2017-06-14 2024-09-04 Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation Proteinaceous heterodimer and use thereof
JP7433051B2 (en) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Uses and methods of IL-2 superagonists, agonists, and fusions thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP2020530440A (en) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド Polynucleotides encoding immunostimulatory fusion molecules and their use
JP2020527025A (en) 2017-07-12 2020-09-03 シンロジック オペレーティング カンパニー インコーポレイテッド Microorganisms programmed to produce immune modulators and anti-cancer therapeutic agents in tumor cells
US20190023760A1 (en) 2017-07-24 2019-01-24 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues
JP7258844B2 (en) 2017-08-03 2023-04-17 シンソークス， インコーポレイテッド Cytokine conjugates for the treatment of proliferative diseases and infectious diseases
KR102758346B1 (en) 2017-08-04 2025-01-24 젠맵 에이/에스 Binding agent that binds to PD-L1 and CD137 and uses thereof
CN117924493A (en) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 CLEC9A binding agents and uses thereof
US11566072B2 (en) 2017-08-09 2023-01-31 Orionis Biosciences, Inc. CD8 binding agents
CA3069994A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Pd-1 and pd-l1 binding agents
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
KR20250040097A (en) 2017-08-18 2025-03-21 그릿스톤 바이오, 인코포레이티드 Antigen-binding proteins tatrgeting shared antigens
US20210115453A1 (en) 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
EP3678677A4 (en) 2017-09-07 2021-06-16 Cue Biopharma, Inc. ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
CN111050793A (en) 2017-09-07 2020-04-21 库尔生物制药有限公司 Polymeric T cell regulatory polypeptides and methods of using the same
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP2020534352A (en) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド T cell regulatory multimeric polypeptide with conjugation site and how to use it
AU2018329741B2 (en) 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CN117430699A (en) 2017-09-30 2024-01-23 合肥立方制药股份有限公司 Proteins binding to fibronectin B domain
US11474271B2 (en) 2017-10-24 2022-10-18 Schlumberger Technology Corporation Methods and systems for automated sonic imaging
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. Nk cells for use in treating cancer in canines
AU2018364114B2 (en) 2017-11-08 2024-09-26 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
EP3710463A1 (en) 2017-11-13 2020-09-23 Extremochem, Lda. Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
CA3082484A1 (en) 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
KR102777151B1 (en) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Partial agonist of interleukin-2
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP3746103A4 (en) 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University PROTEINS MODIFIED TO ENHANCE A CELL'S SENSITIVITY TO IL-2
MX2020005208A (en) 2017-12-06 2020-08-20 Pandion Operations Inc Il-2 muteins and uses thereof.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
SG11202003864XA (en) 2017-12-13 2020-07-29 Janssen Biotech Inc Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
JP7565795B2 (en) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド System and method for determining beneficial administration of tumor infiltrating lymphocytes and methods of use thereof, and beneficial administration of tumor infiltrating lymphocytes and methods of use thereof
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
EP3502139A1 (en) 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
JP7275049B2 (en) 2017-12-27 2023-05-17 協和キリン株式会社 IL-2 variants
JP2021508478A (en) 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ Tumor necrosis factor (TNF) receptor superfamily (TNFRSF) receptor-activated antibody fusion protein with FcγR-independent agonist activity (TNFRSF receptor-activated antibody fusion protein with FcγR-independent agonist activity; TRAAFFIAA)
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
BR112020013848A2 (en) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. methods for expanding tumor-infiltrating lymphocytes and for treating an individual with cancer, tumor-infiltrating lymphocyte population, and, method for evaluating transcription factors
CN111886241A (en) 2018-01-09 2020-11-03 库尔生物制药有限公司 Multimeric T cell modulating polypeptides and methods of use thereof
EP3743438A4 (en) 2018-01-24 2022-02-23 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
WO2019144309A1 (en) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
TWI708787B (en) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1 agonist antibodies and uses thereof
WO2019173636A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
JP7515412B2 (en) 2018-03-09 2024-07-12 アスクジーン・ファーマ・インコーポレイテッド Novel cytokine prodrugs
US12466884B2 (en) 2018-07-09 2025-11-11 Surrozen Operating, Inc. Tissue-specific WNT signal enhancing molecules and uses
AU2019311233B2 (en) 2018-07-24 2025-01-09 BioNTech SE IL2 agonists
EP3876986A4 (en) 2018-09-18 2022-06-01 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CN114679909A (en) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM-targeted immune tolerance
WO2021034890A1 (en) 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
US11095944B2 (en) 2019-08-19 2021-08-17 Roku, Inc. Content-modification system with broadcast schedule utilization feature
EP4107189A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3188732A1 (en) 2020-08-19 2022-02-24 Nathan HIGGINSON-SCOTT Multi-paratopic anti-pd-1 antibodies and uses thereof
US20250019431A1 (en) 2020-10-16 2025-01-16 Pandion Operations, Inc. Kidney targeted immunotolerance
US20240262905A1 (en) 2020-10-16 2024-08-08 Pandion Operations, Inc. Skin targeted immunotolerance

Also Published As

Publication number Publication date
EP3630163A1 (en) 2020-04-08
US20180340014A1 (en) 2018-11-29
CN111010866A (en) 2020-04-14
MX2019013517A (en) 2020-08-17
KR20200010354A (en) 2020-01-30
EP3630163A4 (en) 2021-06-09
JP2020521452A (en) 2020-07-27
CA3064435A1 (en) 2018-11-29
IL270741A (en) 2020-01-30
AU2018273914A1 (en) 2019-11-14
US11466068B2 (en) 2022-10-11
US20210094996A1 (en) 2021-04-01
US10676516B2 (en) 2020-06-09
WO2018217989A1 (en) 2018-11-29
BR112019024127A2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201808990QA (en) Compositions for topical application of compounds
SG11201908391XA (en) Methods for modulating an immune response
SG11201907023UA (en) Method of reducing neutropenia
SG11201811432WA (en) Rna for cancer therapy
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809594WA (en) Nicotine particles and compositions
SG11201805204WA (en) Nicotine particle capsule
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof